Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 18Gynecologic 12Breast 9Thoracic 6Genitourinary 3Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mass Screening × Plasma cell × Clear all
NCT05844033 2026-05-19

Biomarker for Infection Risk in CLL and MM

Massachusetts General Hospital

Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡